Cancer – BrainChild-03: Phase 1 Study of B7-H3-Specific CAR T Cell Locoregional Immunotherapy for Diffuse Intrinsic Pontine Glioma/Diffuse Midline Glioma and Recurrent or Refractory Pediatric Central Nervous System Tumors
Condition or Therapy:
Diffuse intrinsic pontine glioma (DIPG), diffuse midline glioma (DMG), recurrent or refractory central nervous system (CNS) tumors
What is the goal of this study?
In this phase 1 clinical trial, Seattle Children's is testing CAR T-cell therapy in children and young adults with recurrent or refractory central nervous system (CNS) tumors, including diffuse intrinsic pontine glioma (DIPG) and diffuse midline glioma (DMG).
Researchers are working to answer these questions:
- Is this T-cell therapy safe to give to children and young adults with recurrent or refractory CNS tumors, including DIPG and DMG?
- What is the best dose of this therapy?
Who can join the study?
This study might be a good fit for children and young adults who:
- Are ages 1 to 26 years old
- Have recurrent or refractory CNS tumors, including DIPG and DMG
Researchers use many other factors to decide whether or not a patient can take part in a study (called includion or exclusion criteria). The study team at Seattle Children's can explain what these factors mean for you or your child.
What will happen if my child takes part in this study?
In this study, the patient's own T-cells will be reprogrammed to recognize and target B7-H3, which is present on the surface of many pediatric brain tumors.
The reprogrammed cells will be put back into your body (infused) through a catheter, either into the place where a tumor was removed or into the CNS ventricular system (intra-CNS). Placement of this catheter will depend on the location of your tumor.
Read more about the BrainChild-03 study on clinicaltrials.gov.
Who can I contact for more information?
For more information, please call 206-987-2106 or send us an email.